For the past two years, Ozempic has been highly effective maintenance; it dropped my A1c from a pre-diabetic 6.3 to a perfectly normal 5.6. While the clinical results have been steady, the financial relief that I experienced today at the local Walmart was a milestone I have been tracking for months. The generic rollout has been highly anticipated, and this morning, the supply chain finally delivered those savings directly to me.
Because of Canadian government involvement, the cost of the brand-name drug here was always substantially cheaper than south of the border. It averaged around 250 CAD a month, which is a stark contrast to the punishing 900 USD (roughly 1,250 CAD) out-of-pocket costs routinely seen at American pharmacies.
However, the real tipping point came down to an administrative blunder. Canada recently became the first G7 nation to authorize generic versions of semaglutide. This happened largely because Novo Nordisk notoriously failed to pay a 250 CAD patent maintenance fee back in 2019.
That single missed payment caused their Canadian patent to lapse permanently. It opened the door for Health Canada to approve generics years before the US patent expires in 2032, and the financial impact on the ground is immediate and quite staggering.
Let us look at the raw math for the standard 1.00 mg dose pen, drawn directly from my own purchase history at my uptown Walmart:
- March 2026: 246.12 CAD (173.53 USD) for Brand Name Ozempic
- Today: 89.39 CAD (63.02 USD) for Apotex APO-Semaglutide
That is a 63.7% price drop. For anyone paying out of pocket, this changes the calculus entirely. Apotex clearly entered the Canadian market to aggressively undercut the brand name, rather than just offering a token discount. It is a brilliant bit of market disruption, and a very welcome break for the wallet.
